MORPHOLOGICAL MANIFESTATIONS OF EXPERIMENTAL PACLITAXEL-INDUCED SICK NERVE NEUROPATHY UNDER CORRECTION OF 2-ETHYL-6-METHYLIDE-3-HYCYDYR-3-HYDYCIDE-3
DOI:
https://doi.org/10.31618/ESSA.2782-1994.2021.2.68.20Keywords:
paclitaxel, paclitaxel-induced peripheral neuropathy, sciatic nerve, 2-ethyl-6-methyl-3-hydroxypyridine succinate.Abstract
Paclitaxel is an effective chemotherapeutic agent for many cancers, but has a number of limiting side effects that not only significantly reduce the quality of life of patients, but also limit their further treatment. Peripheral neuropathy is one of these, but as of today, there are no proven effective drugs for the prevention or treatment of paclitaxel-induced neuropathic pain (IDP) in particular, or peripheral chemotherapy-induced neuropathy (PIH) in general. 2-ethyl-6-methyl-3-hydroxypyridine succinate (HS) is a derivative of succinic acid with neuroprotective, antihypoxic, membrane-protective, nootropic, sedative action. The experiment was performed on 80 white rats injected intraperitoneally with paclitaxel (Actavis, Romania), pre-dissolved in isotonic saline at a dose of 2 mg / kg body weight four times a day until a total dose of 8 mg / kg. Forty of these animals were then injected intraperitoneally with 2-ethyl-6-methyl-3-hydroxypyridine succinate at a dose of 10 mg / kg (the other 40 rats received intraperitoneal water for injection). Morphological studies were performed on the 1st, 7th, 15th, 28th, 60th, 90th and 120th days after the last administration of the drug. We investigated the pharmacological potential of HS in the prevention and treatment of PNH at the level of the sciatic nerve (CH). Our results allow us to conclude that the introduction of HS creates a protective effect against paclitaxel-induced peripheral neuropathy (PIPN) by affecting both the axial cylinder and the myelin sheath of HF. Due to the known pathophysiological mechanisms of neuropathy, this method can be a promising therapeutic tool for the prevention and treatment of PIPN.
References
Dawn L. et al. Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. JOURNAL OF CLINICAL ONCOLOGY. – 2013. – Jul; 31 (20): 2627-2634.
Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know. J Peripher Nerv Syst. –2014. – Jun;19(2):66-76.
Huang H. Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis. / Huang H., He M., Liu L., Huang L. Contemporary Oncology. – 2016. – 20(3). – P. 237–241.
Schloss J.M. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapyinduced peripheral neuropathy (CIPN). / Schloss J.M., Colosimo M., Airey C., Masci P., Linnane AW., Vitetta L. Support Care Cancer. –2017. – Jan;25(1):195-204.
Gewandter J. S. A Phase III Randomized, Placebo-Controlled Study of Topical Amitriptyline and Ketamine for Chemotherapy-Induced Peripheral Neuropathy (CIPN): A University of Rochester CCOP Study of 462 Cancer Survivors. / Gewandter, J. S., Mohile, S. G., Heckler, C. E., Ryan, J. L., Kirshner, J. J., Flynn, P. J., Morrow, G. R. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. – 2014. – 22(7). – P. 1807-1814.
Peters CM, Jimenez-Andrade JM, Kuskowski MA. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administrtion of paclitaxel in the rat. Brain Res. 2007;1168:46 – 59.
Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S. Pathogenesis of paclitaxelinduced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2020 Feb;324:113121.
Manjavachi MN, Passos GF, Trevisan G, Araujo SB, Pontes JP еа. Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel-induced peripheral neuropathy in mice. Neuropharmacology. 2019 Jun;151:136-143. УДК 617.753.25
Sivanesan E, Stephens KE, Huang Q, Chen Z, Ford NC, Duan W еа. Spinal cord stimulation prevents paclitaxel-induced mechanical and cold hypersensitivity and modulates spinal gene expression in rats. Pain Rep. 2019 Sep 12;4(5):e785.
Dronov SN. Farmakolohyia meksydola y eho prymenenye v psykhonevrolohycheskoi praktyke. Visnyk VDNZU «Ukrainska medychna stomatolohichna akademiia». 2016;15,3(51),1:328-35. [Russian].
Volchehorskyi YA, Moskvycheva MH.
Vlyianye preparata meksydol na proiavlenyia dystalnoi symmetrychnoi polynevropatyy u bolnikh sakharnim dyabetom s syndromom dyabetycheskoi stopy.
Farmateka. 2007;20 (154):76-9. [Russian].
Skopyn P. Vlyianye meksydola na antymetastatycheskuiu aktyvnost protyvoopukholevikh preparatov. Aspyrantskyi vestnyk Povolzhia. 2009;3-4:104-6. [Russian].
Polomano RC, Mannes FJ, Clark US. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, Paclitaxel. Pain. 2001; 94(3):293-304.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.
